<DOC>
	<DOCNO>NCT01642589</DOCNO>
	<brief_summary>The aim study assess safety immunogenicity single dose Menactra® support registration vaccine South Korea . Primary Objective : - To demonstrate seroconversion rate high 60 % serogroups A , C , Y W-135 , 28 day single dose Menactra® . Secondary objective : - To demonstrate superiority Menactra® versus Adacel® term seroconversion rate serogroups A , C , Y , W-135 , 28 day single dose vaccine - To describe safety profile 1 dose Menactra® Adacel® vaccine . - To describe Serum Bactericidal Assay Using Baby Rabbit ( SBA-BR ) Complement titer 28 day single dose Menactra® Adacel® vaccine .</brief_summary>
	<brief_title>Safety Immunogenicity Study Use Menactra® Versus Adacel® Subjects 11 55 Years Age South Korea</brief_title>
	<detailed_description>All participant receive single dose vaccine , assess immunogenicity baseline ( pre-vaccination ) 28 day post-vaccination . Safety data , include serious adverse event ( SAEs ) collect Day 0 Day 28 post-vaccination .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 11 55 year day inclusion Subject age 11 19 year : assent form sign date subject inform consent form sign date least 1 parent another legal representative Subject age 20 55 year : inform consent form sign date subject If subject subject 's parent ( ) legal representative illiterate , independent witness require sign consent form . Subject parent/legally acceptable representative ( applicable ) able attend schedule visit comply trial procedure Covered health insurance . Subject pregnant , lactating , childbearing potential ( consider nonchildbearing potential , female must premenarche post menopausal least 1 year , surgically sterile ( hysterectomy bilateral tubal ligation ) , use effective method contraception abstinence least 4 week prior vaccination , least 4 week vaccination ) Participation 4 week precede trial vaccination plan participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure Receipt plan receipt vaccine 4 week precede follow trial vaccination . Monovalent pandemic influenza vaccine multivalent pandemic influenza vaccine administer time study Previous vaccination meningococcal disease either trial vaccine another vaccine Vaccination diphtheria tetanus past 5 year previous vaccination either Adacel® Tdap vaccine Receipt immune globulin , blood bloodderived product past 3 month Known suspected congenital acquire immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) History invasive meningococcal disease , confirm either clinically , serologically , microbiologically At high risk invasive meningococcal disease trial Known systemic hypersensitivity vaccine component history lifethreatening reaction vaccine use trial vaccine contain substance Thrombocytopenia , bleed disorder receipt anticoagulants 3 week precede inclusion , contraindicate intramuscular vaccination Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction Chronic illness stage could interfere trial conduct completion , opinion investigator Moderate severe acute illness/infection ( accord investigator judgment ) day vaccination febrile illness ( temperature ≥ 38.0°C ) . A prospective subject include study condition resolve febrile event subside Received oral injectable antibiotic therapy within 72 hour prior first blood draw Identified Investigator employee Investigator study center direct involvement propose , identify immediate family member ( i.e . parent , spouse , natural adopt child ) Investigator employee direct involvement propose study Personal history GuillainBarré Syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcal disease</keyword>
	<keyword>Menactra®</keyword>
	<keyword>Adacel®</keyword>
</DOC>